Short Interest in Aprea Therapeutics, Inc. (NASDAQ:APRE) Decreases By 67.2%

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the target of a significant decline in short interest in November. As of November 15th, there was short interest totalling 9,500 shares, a decline of 67.2% from the October 31st total of 29,000 shares. Based on an average daily volume of 22,000 shares, the short-interest ratio is presently 0.4 days. Approximately 0.2% of the shares of the company are sold short.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Aprea Therapeutics in a report on Monday, November 18th. Wedbush reiterated an “outperform” rating and issued a $11.00 target price on shares of Aprea Therapeutics in a research note on Tuesday, August 13th.

Aprea Therapeutics Price Performance

NASDAQ:APRE traded down $0.08 during mid-day trading on Friday, reaching $2.90. The stock had a trading volume of 5,706 shares, compared to its average volume of 19,921. The business has a 50 day simple moving average of $3.31 and a 200 day simple moving average of $3.76. Aprea Therapeutics has a twelve month low of $2.15 and a twelve month high of $8.85.

Aprea Therapeutics (NASDAQ:APRE) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.11. The firm had revenue of $0.35 million for the quarter, compared to analyst estimates of $0.45 million. Aprea Therapeutics had a negative return on equity of 57.86% and a negative net margin of 1,029.50%. Research analysts predict that Aprea Therapeutics will post -2.55 earnings per share for the current year.

Insider Transactions at Aprea Therapeutics

In other news, Director Marc Duey sold 6,462 shares of the firm’s stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $4.58, for a total transaction of $29,595.96. Following the transaction, the director now directly owns 233,651 shares in the company, valued at approximately $1,070,121.58. This trade represents a 2.69 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bernd R. Seizinger purchased 10,000 shares of Aprea Therapeutics stock in a transaction that occurred on Friday, October 11th. The stock was acquired at an average price of $2.68 per share, with a total value of $26,800.00. Following the transaction, the director now owns 44,730 shares in the company, valued at $119,876.40. The trade was a 28.79 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 42,290 shares of company stock worth $165,096. Corporate insiders own 12.80% of the company’s stock.

Institutional Trading of Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Dimensional Fund Advisors LP bought a new stake in Aprea Therapeutics, Inc. (NASDAQ:APRE) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned approximately 0.20% of Aprea Therapeutics at the end of the most recent quarter. Institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.